Core Scientific Inc (NASDAQ:CORZ) reported financial results for the fourth quarter of 2025 that fell short of analyst expectations, sending its shares lower in after-hours trading. The company, which is undergoing a significant strategic pivot from bitcoin mining to high-density colocation for artificial intelligence workloads, posted a mixed quarter that highlighted both the progress and the substantial costs of its transition.
Earnings and Revenue Versus Estimates
The company's top and bottom-line results for Q4 2025 missed Wall Street forecasts. Core Scientific reported total revenue of $79.8 million, a significant decline from the $94.9 million generated in the same period last year. This result was well below the analyst consensus estimate of approximately $124.5 million.
On a per-share basis, the company reported a non-GAAP loss of $0.29. This was notably wider than the estimated loss of $0.0861 per share anticipated by analysts.
The key drivers behind these figures were:
- Strategic Shift Impact: A deliberate reduction in digital asset self-mining revenue, which fell to $42.2 million from $79.9 million in Q4 2024. This was driven by a 57% decrease in the amount of bitcoin mined as the company repurposes facilities.
- Colocation Growth: A substantial increase in colocation revenue, which rose to $31.3 million from $8.5 million a year ago, reflecting the early stages of its strategic build-out.
- Increased Costs: The quarter was burdened by significant expenses related to the business transition, including $61.7 million in fair value losses on digital assets, $11.4 million in property impairments, and $8.8 million in colocation startup costs.
Market Reaction and Price Action
The market's immediate reaction to the earnings miss was negative. Following the release, Core Scientific's stock traded lower in the extended session. This price action suggests investor disappointment with the larger-than-expected loss and the revenue shortfall, overshadowing the strategic narrative of the colocation build-out.
The negative weekly and monthly performance figures provided—showing declines of approximately 2.4% over the past week and 8.3% over the past month—indicate that bearish sentiment or caution was already present in the market leading up to the earnings announcement. The post-release decline appears to be a continuation of this trend, amplified by the disappointing quarterly numbers.
Strategic Pivot and Financial Highlights
The earnings report centered on the company's ongoing transformation. CEO Adam Sullivan stated the company is scaling its colocation platform toward a "1.5 gigawatt pipeline of leasable capacity" and accelerating timelines across multiple sites.
Key financial and operational takeaways from the release include:
- Capital Expenditures & Funding: Q4 capital expenditures were $279.2 million, with $226.2 million of that funded by customer CoreWeave, Inc. pursuant to existing agreements, alleviating some of the cash burden on Core Scientific.
- Liquidity Position: The company ended the quarter with $533.4 million in liquidity, comprising $311.4 million in cash and $222.0 million in bitcoin.
- Restatement of Financials: Core Scientific announced a restatement of previously issued financial statements for 2024 and parts of 2025 due to an accounting error related to the capitalization of assets committed to demolition during facility conversions. The company emphasized this had no impact on revenue, adjusted EBITDA, or cash flows for the affected periods.
- Profitability Metrics: While the company reported a net income of $216.0 million for the quarter, this was primarily due to a non-cash, fair value gain of $330.3 million on warrant liabilities. The operating loss was $117.5 million, and the non-GAAP Adjusted EBITDA was negative $42.7 million.
Looking Ahead
Management's commentary focused on the future potential of the colocation business rather than providing specific quantitative financial guidance for the coming quarters. The reported analyst estimates for Core Scientific project significant growth, with full-year 2026 sales estimated at $819.7 million and a per-share loss of $0.1336. For the upcoming first quarter of 2026, analysts are forecasting revenue of $163.6 million and a loss of $0.0493 per share. Investors will be watching closely to see if the company's execution can begin to align with these growth expectations in the near term.
For a detailed look at Core Scientific's historical earnings and future analyst estimates, you can review the data here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
